US FDA News

top of page

FDA Approves Novartis' Pluvicto for Earlier Treatment of Prostate Cancer | iPharmaCenter

ipharmaservices

Apr 3

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

ipharmaservices

Mar 5

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

ipharmaservices

Feb 3

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

ipharmaservices

Jan 29

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

ipharmaservices

Jan 3

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

ipharmaservices

Dec 23, 2024

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

ipharmaservices

Oct 13, 2024

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

ipharmaservices

Oct 13, 2024

US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter

ipharmaservices

Oct 9, 2024

FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter

ipharmaservices

Aug 24, 2024

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

ipharmaservices

Aug 8, 2024

FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata

ipharmaservices

Aug 8, 2024

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

ipharmaservices

Aug 5, 2024

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

ipharmaservices

Jul 4, 2024

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

ipharmaservices

Jun 20, 2024

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

ipharmaservices

Jun 19, 2024

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

ipharmaservices

Jun 18, 2024

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

ipharmaservices

May 31, 2024

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

ipharmaservices

May 16, 2024

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

ipharmaservices

Apr 30, 2024

bottom of page